FDA DEVICE FACTS
XIENCE V AND NANO EVEROLIMUS ELUTING CORONARY STENT SYSTEM
Abbott Vascular, Inc.
Verified FDA Record identity for medical-device development research. This overview uses only fields stated in the FDA Record and is not a Device Description.医療機器開発の調査用に、確認済みの FDA Record の識別情報を示しています。この概要は FDA Record に記載された項目だけによるもので、機器説明ではありません。
Indications for use
The XIENCE V and XIENCE nano Everolimus Eluting Coronary Stent System is indicated for improving coronary luminal diameter in patients, including those with diabetes mellitus, with symptomatic heart disease due to de novo native coronary artery lesions (length ≤ 28 mm) with reference vessel diameters of 2.25 mm to 4.25 mm. Additionally, the XIENCE V stent system is indicated for treating de novo chronic total coronary occlusions. XIENCE PRIME and XIENCE PRIME LL Everolimus Eluting Coronary Stent System The XIENCE PRIME and XIENCE PRIME LL Everolimus Eluting Coronary Stent System is indicated for improving coronary luminal diameter in patients, including those with diabetes mellitus, with symptomatic heart disease due to de novo native coronary artery lesions (length ≤ 32 mm) with reference vessel diameters of ≥ 2.25 mm to ≤ 4.25 mm. Additionally, the XIENCE PRIME stent system is indicated for treating de novo chronic total coronary occlusions. XIENCE Xpedition, XIENCE Xpedition SV and XIENCE Xpedition LL Everolimus Eluting Coronary Stent System
The XIENCE Xpedition, XIENCE Xpedition SV and XIENCE Xpedition LL Everolimus Eluting Coronary Stent System is indicated for improving coronary artery luminal diameter in patients, including those with diabetes mellitus, with symptomatic heart disease due to de novo native coronary artery lesions (length ≤ 32 mm) with reference vessel diameters of ≥ 2.25 mm to ≤ 4.25 mm. In addition, the XIENCE Xpedition stent system is indicated for treating de novo chronic total coronary occlusions.
The XIENCE Alpine Everolimus Eluting Coronary Stent System is indicated for improving coronary artery luminal diameter in patients with symptomatic heart disease, including those with diabetes mellitus, due to de novo native coronary artery lesions (length ≤ 32 mm) with reference vessel diameters of ≥ 2.25 mm to ≤ 4.25 mm. Additionally, the XIENCE Alpine stent system is indicated for treating de novo chronic total coronary occlusions.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。